



UBC BC Cancer Research Ethics Board
 Fairmont Medical Building
 750 West Broadway, Suite 1315
 Vancouver, BC V5Z 1J3
 Tel: (604) 877-6223
 E-mail: reb@bccancer.bc.ca
 Website: <http://www.bccancer.bc.ca/our-research/ethics-oversight/research-ethics-board>
 RISE: <http://rise.ubc.ca>

University of British Columbia - BC Cancer Research
 Ethics Board (UBC BC Cancer REB)

Certificate of Expedited Approval

PRINCIPAL INVESTIGATOR: Sharlene Gill	INSTITUTION / DEPARTMENT: Systemic Therapy - Vancouver (BC Cancer)	REB NUMBER: H19-01865
INSTITUTION(S) WHERE RESEARCH WILL BE CARRIED OUT:		
Institution	Site	
BC Cancer	Vancouver	
Other locations where the research will be conducted: N/A		
PRINCIPAL INVESTIGATOR FOR EACH ADDITIONAL PARTICIPATING BC CANCER CENTRE:		
Vancouver:	Sharlene Gill	Vancouver Island: N/A
Fraser Valley:	N/A	Southern Interior: N/A
Abbotsford Centre:	N/A	Centre for the North: N/A
SPONSORING AGENCIES AND COORDINATING GROUPS: N/A		
PROJECT TITLE: Treatment Attrition Rates in Metastatic Esophagogastric Cancer		

The UBC BC Cancer Research Ethics Board Chair, Vice-Chair or second Vice-Chair, has reviewed the above described research project, including associated documentation noted below, and finds the research project acceptable on ethical grounds for research involving human subjects and hereby grants approval.

This approval applies to research ethics issues only. The approval does not obligate an institution or any of its departments to proceed with activation of the study. The Principal Investigator for the study is responsible for identifying and ensuring that institutional policies such as those related to conflict of interest and privacy protection are followed, and that resource impacts from this study are properly negotiated. The REB assumes that investigators and the coordinating office of all trials continuously review new information for findings that indicate a change should be made to the protocol, consent documents or conduct of the trial and that such changes will be brought to the attention of the REB in a timely manner.

EXPIRY DATE OF THIS APPROVAL: July 12, 2020

DATE DOCUMENT(S) APPROVED: July 12, 2019

LIST OF DOCUMENTS APPROVED:

Document Name	Version	Date
Protocol: Treatment Attrition Rates in Advanced Esophagogastric Cancer Proposal	1.0	June 18, 2019
Other Documents: Treatment Attrition Rates in Advanced Esophagogastric Cancer Data	1.0	June 18, 2019

Collection Form

REB COMMENTS:

CERTIFICATION:

1. The membership of the UBC BC Cancer REB complies with the membership requirements for research ethics boards defined in Division 5 of the Food and Drug Regulations of Canada.
2. The UBC BC Cancer REB carries out its functions in a manner fully consistent with Good Clinical Practices.
3. The UBC BC Cancer REB has reviewed and approved the research project named on this Certificate of Approval including any associated consent form and taken the action noted above. This research project is to be conducted by the provincial investigator named above. This review and the associated minutes of the UBC BC Cancer REB have been documented electronically and in writing.

UBC BC Cancer Research Ethics Board approval or acknowledgement of the above has been provided by either the full board or where delegated approval is applicable, an authorized delegated reviewer.

Electronic verification of appropriate authorization is maintained within a UBC secure encrypted web based system.

UBC BC Cancer REB membership list is available at: <http://www.bccancer.bc.ca/our-research/ethics-oversight/research-ethics-board>

If you have any questions, please contact the UBC BC Cancer REB Administration

Tel: (604) 877-6223

E-mail: reb@bccancer.bc.ca